Differential Expression and Prognostic Implications of the CCN Family Members WISP-1, WISP-2, and WISP-3 in Human Breast Cancer
The CCN family has three Wnt-inducted secreted proteins named WISP-1, WISP-2 and WISP-3. These molecules are known to play a diverse role in cells, but their role in cancer cells remains controversial. In this study, we analyzed the expression of the three WISP molecules at the mRNA and protein leve...
Saved in:
Published in | Annals of surgical oncology Vol. 14; no. 6; pp. 1909 - 1918 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
Springer Nature B.V
01.06.2007
|
Subjects | |
Online Access | Get full text |
ISSN | 1068-9265 1534-4681 |
DOI | 10.1245/s10434-007-9376-x |
Cover
Abstract | The CCN family has three Wnt-inducted secreted proteins named WISP-1, WISP-2 and WISP-3. These molecules are known to play a diverse role in cells, but their role in cancer cells remains controversial.
In this study, we analyzed the expression of the three WISP molecules at the mRNA and protein levels in a cohort of 122 human breast tumors and 32 normal breast tissues, and we correlated these findings with patients' clinical outcomes.
WISP-1 transcripts were found in lower levels in node-positive tumors compared with node-negative tumors (P < .05); were lower in patients with a moderate (P = .01) and poor Nottingham Prognostic Index prognosis (P < .05) compared with good prognostic groups; were of significantly lower level in grade 3 differentiated tumors (P < .05) compared with grade 1; and were of lower levels in patients who developed metastasis and died from breast cancer-related causes (P < .05 in both comparisons). Almost the reverse was found to be true for WISP-2, which had greater levels of expression in node-positive tumors (P = .0043); higher levels in both moderate and poor prognostic groups compared with the good prognostic group (both P < .05); greater level in both grade 2 and 3 when compared with grade 1 (both P < .05); and higher levels in patients who went on to develop metastases (P < .01). WISP-3 transcript levels showed no statistically significant differences between groups.
WISPs may play important but contrasting roles in breast cancer. WISP-1 seems to act as a tumor suppressor and WISP-2 as a factor that stimulates aggressiveness; WISP-3 has no definable beneficial or detrimental role. |
---|---|
AbstractList | The CCN family has three Wnt-inducted secreted proteins named WISP-1, WISP-2 and WISP-3. These molecules are known to play a diverse role in cells, but their role in cancer cells remains controversial.
In this study, we analyzed the expression of the three WISP molecules at the mRNA and protein levels in a cohort of 122 human breast tumors and 32 normal breast tissues, and we correlated these findings with patients' clinical outcomes.
WISP-1 transcripts were found in lower levels in node-positive tumors compared with node-negative tumors (P < .05); were lower in patients with a moderate (P = .01) and poor Nottingham Prognostic Index prognosis (P < .05) compared with good prognostic groups; were of significantly lower level in grade 3 differentiated tumors (P < .05) compared with grade 1; and were of lower levels in patients who developed metastasis and died from breast cancer-related causes (P < .05 in both comparisons). Almost the reverse was found to be true for WISP-2, which had greater levels of expression in node-positive tumors (P = .0043); higher levels in both moderate and poor prognostic groups compared with the good prognostic group (both P < .05); greater level in both grade 2 and 3 when compared with grade 1 (both P < .05); and higher levels in patients who went on to develop metastases (P < .01). WISP-3 transcript levels showed no statistically significant differences between groups.
WISPs may play important but contrasting roles in breast cancer. WISP-1 seems to act as a tumor suppressor and WISP-2 as a factor that stimulates aggressiveness; WISP-3 has no definable beneficial or detrimental role. BackgroundThe CCN family has three Wnt-inducted secreted proteins named WISP-1, WISP-2 and WISP-3. These molecules are known to play a diverse role in cells, but their role in cancer cells remains controversial.MethodsIn this study, we analyzed the expression of the three WISP molecules at the mRNA and protein levels in a cohort of 122 human breast tumors and 32 normal breast tissues, and we correlated these findings with patients’ clinical outcomes.ResultsWISP-1 transcripts were found in lower levels in node-positive tumors compared with node-negative tumors (P < .05); were lower in patients with a moderate (P = .01) and poor Nottingham Prognostic Index prognosis (P < .05) compared with good prognostic groups; were of significantly lower level in grade 3 differentiated tumors (P < .05) compared with grade 1; and were of lower levels in patients who developed metastasis and died from breast cancer–related causes (P < .05 in both comparisons). Almost the reverse was found to be true for WISP-2, which had greater levels of expression in node-positive tumors (P = .0043); higher levels in both moderate and poor prognostic groups compared with the good prognostic group (both P < .05); greater level in both grade 2 and 3 when compared with grade 1 (both P < .05); and higher levels in patients who went on to develop metastases (P < .01). WISP-3 transcript levels showed no statistically significant differences between groups.ConclusionsWISPs may play important but contrasting roles in breast cancer. WISP-1 seems to act as a tumor suppressor and WISP-2 as a factor that stimulates aggressiveness; WISP-3 has no definable beneficial or detrimental role. The CCN family has three Wnt-inducted secreted proteins named WISP-1, WISP-2 and WISP-3. These molecules are known to play a diverse role in cells, but their role in cancer cells remains controversial. In this study, we analyzed the expression of the three WISP molecules at the mRNA and protein levels in a cohort of 122 human breast tumors and 32 normal breast tissues, and we correlated these findings with patients' clinical outcomes. WISP-1 transcripts were found in lower levels in node-positive tumors compared with node-negative tumors (P < .05); were lower in patients with a moderate (P = .01) and poor Nottingham Prognostic Index prognosis (P < .05) compared with good prognostic groups; were of significantly lower level in grade 3 differentiated tumors (P < .05) compared with grade 1; and were of lower levels in patients who developed metastasis and died from breast cancer-related causes (P < .05 in both comparisons). Almost the reverse was found to be true for WISP-2, which had greater levels of expression in node-positive tumors (P = .0043); higher levels in both moderate and poor prognostic groups compared with the good prognostic group (both P < .05); greater level in both grade 2 and 3 when compared with grade 1 (both P < .05); and higher levels in patients who went on to develop metastases (P < .01). WISP-3 transcript levels showed no statistically significant differences between groups. WISPs may play important but contrasting roles in breast cancer. WISP-1 seems to act as a tumor suppressor and WISP-2 as a factor that stimulates aggressiveness; WISP-3 has no definable beneficial or detrimental role. The CCN family has three Wnt-inducted secreted proteins named WISP-1, WISP-2 and WISP-3. These molecules are known to play a diverse role in cells, but their role in cancer cells remains controversial.BACKGROUNDThe CCN family has three Wnt-inducted secreted proteins named WISP-1, WISP-2 and WISP-3. These molecules are known to play a diverse role in cells, but their role in cancer cells remains controversial.In this study, we analyzed the expression of the three WISP molecules at the mRNA and protein levels in a cohort of 122 human breast tumors and 32 normal breast tissues, and we correlated these findings with patients' clinical outcomes.METHODSIn this study, we analyzed the expression of the three WISP molecules at the mRNA and protein levels in a cohort of 122 human breast tumors and 32 normal breast tissues, and we correlated these findings with patients' clinical outcomes.WISP-1 transcripts were found in lower levels in node-positive tumors compared with node-negative tumors (P < .05); were lower in patients with a moderate (P = .01) and poor Nottingham Prognostic Index prognosis (P < .05) compared with good prognostic groups; were of significantly lower level in grade 3 differentiated tumors (P < .05) compared with grade 1; and were of lower levels in patients who developed metastasis and died from breast cancer-related causes (P < .05 in both comparisons). Almost the reverse was found to be true for WISP-2, which had greater levels of expression in node-positive tumors (P = .0043); higher levels in both moderate and poor prognostic groups compared with the good prognostic group (both P < .05); greater level in both grade 2 and 3 when compared with grade 1 (both P < .05); and higher levels in patients who went on to develop metastases (P < .01). WISP-3 transcript levels showed no statistically significant differences between groups.RESULTSWISP-1 transcripts were found in lower levels in node-positive tumors compared with node-negative tumors (P < .05); were lower in patients with a moderate (P = .01) and poor Nottingham Prognostic Index prognosis (P < .05) compared with good prognostic groups; were of significantly lower level in grade 3 differentiated tumors (P < .05) compared with grade 1; and were of lower levels in patients who developed metastasis and died from breast cancer-related causes (P < .05 in both comparisons). Almost the reverse was found to be true for WISP-2, which had greater levels of expression in node-positive tumors (P = .0043); higher levels in both moderate and poor prognostic groups compared with the good prognostic group (both P < .05); greater level in both grade 2 and 3 when compared with grade 1 (both P < .05); and higher levels in patients who went on to develop metastases (P < .01). WISP-3 transcript levels showed no statistically significant differences between groups.WISPs may play important but contrasting roles in breast cancer. WISP-1 seems to act as a tumor suppressor and WISP-2 as a factor that stimulates aggressiveness; WISP-3 has no definable beneficial or detrimental role.CONCLUSIONSWISPs may play important but contrasting roles in breast cancer. WISP-1 seems to act as a tumor suppressor and WISP-2 as a factor that stimulates aggressiveness; WISP-3 has no definable beneficial or detrimental role. |
Author | Watkins, Gareth Jiang, Wen G. Davies, Simon R. Mansel, Robert E. |
Author_xml | – sequence: 1 givenname: Simon R. surname: Davies fullname: Davies, Simon R. – sequence: 2 givenname: Gareth surname: Watkins fullname: Watkins, Gareth – sequence: 3 givenname: Robert E. surname: Mansel fullname: Mansel, Robert E. – sequence: 4 givenname: Wen G. surname: Jiang fullname: Jiang, Wen G. |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/17406949$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kU1v1DAQhi1URL_4AVyQBRKnho7jr-QIoaUrlbYSII6W40zAVeIsdiJtT_x13N0ipEpwmtHM844sP4dkL0wBCXnB4C0rhTxNDAQXBYAuaq5VsXlCDpjME6Eqtpd7UFVRl0ruk8OUbgGY5iCfkX2mBaha1Afk1wff9xgxzN4O9GyzjpiSnwK1oaM3cfoepjR7R1fjevDOznmV6NTT-QfSprmi53b0wx39hGOLMdFvq883BTvZ1fJke2Xbc-oDvVhGG-j7iDbNtLHBYTwmT3s7JHz-UI_I1_OzL81FcXn9cdW8uyycKGEuGOdcI2rOJbYgAbpat9ArYTnHVgshoGJcMNtVnRDYOatEz0Xv2rKrhWP8iLzZ3V3H6eeCaTajTw6HwQaclmQ0SFmLimfw9SPwdlpiyG8zpVIKalAgM_Xqn1SpuVIl1xl6-QAt7YidWUc_2nhn_vx-BtgOcHFKKWL_FwFzb9jsDJts2NwbNpuc0Y8yzs9bL3O0fvhP8jd2CKa5 |
CitedBy_id | crossref_primary_10_1515_hmbci_2015_0001 crossref_primary_10_5483_BMBRep_2018_51_10_192 crossref_primary_10_1371_journal_pcbi_1003409 crossref_primary_10_1016_j_ejca_2008_08_024 crossref_primary_10_1016_j_tibs_2008_07_006 crossref_primary_10_1186_s13287_017_0579_1 crossref_primary_10_1007_s12079_012_0158_2 crossref_primary_10_1038_nrclinonc_2009_73 crossref_primary_10_3892_or_2015_3709 crossref_primary_10_1002_jbmr_3891 crossref_primary_10_3389_fgene_2020_00502 crossref_primary_10_1172_jci_insight_95824 crossref_primary_10_3390_ijms151121011 crossref_primary_10_1016_j_blre_2008_07_002 crossref_primary_10_1016_j_jbc_2023_102971 crossref_primary_10_18632_oncotarget_13021 crossref_primary_10_1007_s00405_013_2740_5 crossref_primary_10_1186_s12905_025_03608_3 crossref_primary_10_1186_1755_8794_6_S1_S4 crossref_primary_10_3892_ijmm_2015_2390 crossref_primary_10_18632_oncotarget_3358 crossref_primary_10_1186_s12967_024_05364_8 crossref_primary_10_1186_s13046_019_1108_0 crossref_primary_10_1177_1535370221992703 crossref_primary_10_3892_ol_2016_5218 crossref_primary_10_1097_MD_0000000000017604 crossref_primary_10_4143_crt_2017_104 crossref_primary_10_1016_j_cellsig_2016_07_009 crossref_primary_10_1097_MD_0000000000017854 crossref_primary_10_1039_c2ib20053h crossref_primary_10_1111_pcmr_12194 crossref_primary_10_3389_fgene_2021_649387 crossref_primary_10_1111_coa_13281 crossref_primary_10_1136_jcp_2010_082768 crossref_primary_10_34172_ajmb_2019_08 crossref_primary_10_1002_cre2_301 crossref_primary_10_1016_j_cllc_2014_12_008 crossref_primary_10_1158_0008_5472_CAN_08_1461 crossref_primary_10_1007_s12079_016_0343_9 crossref_primary_10_1007_s12079_016_0345_7 crossref_primary_10_1016_j_intimp_2024_113791 crossref_primary_10_1016_j_jnutbio_2011_03_010 crossref_primary_10_18632_aging_203424 crossref_primary_10_1038_s41423_022_00930_w crossref_primary_10_4103_1673_5374_155427 crossref_primary_10_1007_s12079_009_0048_4 crossref_primary_10_1002_jcp_28253 crossref_primary_10_3892_or_2013_2909 crossref_primary_10_1186_s12967_019_1769_7 crossref_primary_10_1158_0008_5472_CAN_18_2098 crossref_primary_10_1177_1933719118756749 crossref_primary_10_1186_s12935_021_02116_2 crossref_primary_10_1038_onc_2011_142 crossref_primary_10_3892_ol_2014_2663 crossref_primary_10_1136_jcp_2007_052795 crossref_primary_10_1074_jbc_M111_225755 crossref_primary_10_1038_bjc_2015_285 crossref_primary_10_1016_j_biocel_2015_03_007 crossref_primary_10_1038_srep08686 crossref_primary_10_1093_carcin_bgt373 crossref_primary_10_1097_CAD_0000000000001687 crossref_primary_10_1038_leu_2008_359 |
Cites_doi | 10.1677/erc.1.00825 10.1093/nar/25.12.2516 10.1186/bcr1351 10.1593/neo.03316 10.1053/gast.2001.29570 10.1002/ijc.11302 10.1007/s00384-005-0002-8 10.1136/mp.56.2.80 10.1002/jcp.10315 10.1073/pnas.95.11.6355 10.1158/0008-5472.439.65.2 10.1677/joe.0.1780169 10.1023/B:CLIN.0000017168.83616.d0 10.1186/1475-2867-3-15 10.1245/ASO.2006.05.028 10.1158/1541-7786.MCR-04-0130 10.1186/bcr815 10.1111/j.1365-2559.2005.02104.x 10.1038/bjc.1997.596 10.1245/ASO.2005.10.907 10.1242/jcs.03270 10.1006/bbrc.2001.4584 10.1073/pnas.95.25.14717 10.1016/S0022-5347(05)67869-X 10.1016/S1476-5586(03)80018-0 10.1074/jbc.M210945200 10.1093/molehr/gah028 |
ContentType | Journal Article |
Copyright | Society of Surgical Oncology 2007 Society of Surgical Oncology 2007. |
Copyright_xml | – notice: Society of Surgical Oncology 2007 – notice: Society of Surgical Oncology 2007. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 |
DOI | 10.1245/s10434-007-9376-x |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE Oncogenes and Growth Factors Abstracts Oncogenes and Growth Factors Abstracts MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1534-4681 |
EndPage | 1918 |
ExternalDocumentID | 1282625731 17406949 10_1245_s10434_007_9376_x |
Genre | Research Support, Non-U.S. Gov't Journal Article Comparative Study |
GroupedDBID | --- -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 199 1N0 1SB 203 23M 28- 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2WC 2~H 30V 4.4 406 408 409 40D 40E 53G 5GY 5QI 5VS 67Z 6J9 6NX 78A 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AAPKM AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYXX AAYZH ABAKF ABBBX ABBRH ABBXA ABDBE ABDZT ABECU ABFSG ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABOCM ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACBXY ACDTI ACGFO ACGFS ACHSB ACHVE ACHXU ACIHN ACKNC ACMDZ ACMFV ACMLO ACOKC ACOMO ACPIV ACPRK ACREN ACSTC ACUDM ACZOJ ADBBV ADHHG ADHIR ADHKG ADIMF ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYOE ADZKW AEAQA AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AEZWR AFBBN AFDZB AFEXP AFHIU AFJLC AFKRA AFLOW AFOHR AFQWF AFWTZ AFYQB AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGQPQ AGRTI AGVAE AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHPBZ AHSBF AHWEU AHYZX AIAKS AIGIU AIIXL AILAN AITGF AIXLP AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG ATHPR AVWKF AXYYD AYFIA AZFZN B-. BA0 BAWUL BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI C1A CAG CCPQU CITATION COF CS3 CSCUP DDRTE DIK DL5 DNIVK DPUIP E3Z EBD EBLON EBS EIOEI EJD EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ7 GQ8 GRRUI GXS H13 HEOXT HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IH2 IHE IJ- IKXTQ IMOTQ IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH L7B LAS LLZTM M1P M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD OWW P19 P2P P9S PF0 PHGZM PHGZT PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 WOQ YFH YLTOR Z45 ZMTXR ZOVNA CGR CUY CVF ECM EIF NPM 3V. 7TO 7XB 8FK ABRTQ H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI 7X8 PUEGO |
ID | FETCH-LOGICAL-c420t-13337ee7335eb0500d97b0f64a33eb7444081341ad8d44edca64f34fcb2d94c13 |
IEDL.DBID | 7X7 |
ISSN | 1068-9265 |
IngestDate | Fri Sep 05 12:41:22 EDT 2025 Sat Aug 16 17:21:13 EDT 2025 Sat Aug 23 12:24:57 EDT 2025 Thu Apr 03 06:59:50 EDT 2025 Tue Jul 01 02:08:14 EDT 2025 Thu Apr 24 23:12:14 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c420t-13337ee7335eb0500d97b0f64a33eb7444081341ad8d44edca64f34fcb2d94c13 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
PMID | 17406949 |
PQID | 227366237 |
PQPubID | 32486 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_70559483 proquest_journals_2666090605 proquest_journals_227366237 pubmed_primary_17406949 crossref_primary_10_1245_s10434_007_9376_x crossref_citationtrail_10_1245_s10434_007_9376_x |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2007-06-01 |
PublicationDateYYYYMMDD | 2007-06-01 |
PublicationDate_xml | – month: 06 year: 2007 text: 2007-06-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: New York |
PublicationTitle | Annals of surgical oncology |
PublicationTitleAlternate | Ann Surg Oncol |
PublicationYear | 2007 |
Publisher | Springer Nature B.V |
Publisher_xml | – name: Springer Nature B.V |
References | D Xie (9376_CR5) 2001; 61 A Babic (9376_CR30) 1998; 2695 K Van Golen (9376_CR33) 1999; 5 W Jiang (9376_CR23) 2001; 7 M Zoubine (9376_CR32) 2001; 282 N Planque (9376_CR1) 2003; 3 WG Jiang (9376_CR25) 2004; 11 M Nessling (9376_CR11) 2005; 65 L Ye (9376_CR20) 2003; 196 D Pennica (9376_CR6) 1998; 95 S Chappell (9376_CR12) 1997; 76 L Soon (9376_CR8) 2003; 278 Y Zhang (9376_CR14) 2005; 7 T Khor (9376_CR7) 2006; 21 G Davies (9376_CR27) 2006; 29 G Davies (9376_CR28) 2004; 21 T Martin (9376_CR16) 2005; 12 H Mason (9376_CR31) 2004; 10 J King (9376_CR21) 2004; 6 C Parr (9376_CR22) 2004; 14 TA Martin (9376_CR26) 2005; 46 L Thorstensen (9376_CR34) 2001; 121 S Banerjee (9376_CR9) 2005; 3 A Nazarenko (9376_CR18) 1997; 25 S Banerjee (9376_CR10) 2003; 5 S Hanavadi (9376_CR15) 2006; 13 A Leask (9376_CR4) 2006; 119 C Kleer (9376_CR13) 2004; 6 G Davies (9376_CR24) 2000; 163 W Jiang (9376_CR29) 2004; 11 B Perbal (9376_CR3) 2003; 56 W Jiang (9376_CR17) 2003; 9 D Bringstock (9376_CR2) 2003; 178 W Jiang (9376_CR19) 2003; 106 |
References_xml | – volume: 11 start-page: 781 year: 2004 ident: 9376_CR25 publication-title: Endocr Relat Cancer doi: 10.1677/erc.1.00825 – volume: 25 start-page: 2516 year: 1997 ident: 9376_CR18 publication-title: Nucleic Acids Res doi: 10.1093/nar/25.12.2516 – volume: 5 start-page: 2511 year: 1999 ident: 9376_CR33 publication-title: Clin Cancer Res – volume: 7 start-page: 1080 year: 2005 ident: 9376_CR14 publication-title: Breast Cancer Res doi: 10.1186/bcr1351 – volume: 6 start-page: 179 year: 2004 ident: 9376_CR13 publication-title: Neoplasia doi: 10.1593/neo.03316 – volume: 121 start-page: 1275 year: 2001 ident: 9376_CR34 publication-title: Gastroenterology doi: 10.1053/gast.2001.29570 – volume: 106 start-page: 752 year: 2003 ident: 9376_CR19 publication-title: Int J Cancer doi: 10.1002/ijc.11302 – volume: 14 start-page: 779 year: 2004 ident: 9376_CR22 publication-title: Int J Mol Med – volume: 21 start-page: 291 year: 2006 ident: 9376_CR7 publication-title: Int J Colorectal Dis doi: 10.1007/s00384-005-0002-8 – volume: 56 start-page: 80 year: 2003 ident: 9376_CR3 publication-title: Mol Pathol doi: 10.1136/mp.56.2.80 – volume: 196 start-page: 362 year: 2003 ident: 9376_CR20 publication-title: J Cell Physiol doi: 10.1002/jcp.10315 – volume: 11 start-page: 781 year: 2004 ident: 9376_CR29 publication-title: Endocr Relat Cancer doi: 10.1677/erc.1.00825 – volume: 2695 start-page: 6355 year: 1998 ident: 9376_CR30 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.95.11.6355 – volume: 65 start-page: 439 year: 2005 ident: 9376_CR11 publication-title: Cancer Res doi: 10.1158/0008-5472.439.65.2 – volume: 178 start-page: 169 year: 2003 ident: 9376_CR2 publication-title: J Endocrinol doi: 10.1677/joe.0.1780169 – volume: 21 start-page: 31 year: 2004 ident: 9376_CR28 publication-title: Clin Exp Metastasis doi: 10.1023/B:CLIN.0000017168.83616.d0 – volume: 3 start-page: 15 year: 2003 ident: 9376_CR1 publication-title: Cancer Cell Int doi: 10.1186/1475-2867-3-15 – volume: 13 start-page: 802 year: 2006 ident: 9376_CR15 publication-title: Ann Surg Oncol doi: 10.1245/ASO.2006.05.028 – volume: 7 start-page: 2555 year: 2001 ident: 9376_CR23 publication-title: Clin Cancer Res – volume: 3 start-page: 151 year: 2005 ident: 9376_CR9 publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-04-0130 – volume: 6 start-page: 478 year: 2004 ident: 9376_CR21 publication-title: Breast Cancer Res doi: 10.1186/bcr815 – volume: 46 start-page: 422 year: 2005 ident: 9376_CR26 publication-title: Histopathology doi: 10.1111/j.1365-2559.2005.02104.x – volume: 76 start-page: 1558 year: 1997 ident: 9376_CR12 publication-title: Br J Cancer doi: 10.1038/bjc.1997.596 – volume: 12 start-page: 1 year: 2005 ident: 9376_CR16 publication-title: Ann Surg Oncol doi: 10.1245/ASO.2005.10.907 – volume: 119 start-page: 4803 year: 2006 ident: 9376_CR4 publication-title: J Cell Sci doi: 10.1242/jcs.03270 – volume: 61 start-page: 8917 year: 2001 ident: 9376_CR5 publication-title: Cancer Res – volume: 282 start-page: 421 year: 2001 ident: 9376_CR32 publication-title: Biochem Biophys Res Commun doi: 10.1006/bbrc.2001.4584 – volume: 95 start-page: 14717 year: 1998 ident: 9376_CR6 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.95.25.14717 – volume: 163 start-page: 985 year: 2000 ident: 9376_CR24 publication-title: J Urol doi: 10.1016/S0022-5347(05)67869-X – volume: 29 start-page: 1311 year: 2006 ident: 9376_CR27 publication-title: Int J Oncol – volume: 5 start-page: 63 year: 2003 ident: 9376_CR10 publication-title: Neoplasia doi: 10.1016/S1476-5586(03)80018-0 – volume: 9 start-page: 6432 year: 2003 ident: 9376_CR17 publication-title: Clin Can Res – volume: 278 start-page: 11465 year: 2003 ident: 9376_CR8 publication-title: J Biol Chem doi: 10.1074/jbc.M210945200 – volume: 10 start-page: 181 year: 2004 ident: 9376_CR31 publication-title: Mol Hum Reprod doi: 10.1093/molehr/gah028 |
SSID | ssj0017305 |
Score | 2.1552124 |
Snippet | The CCN family has three Wnt-inducted secreted proteins named WISP-1, WISP-2 and WISP-3. These molecules are known to play a diverse role in cells, but their... BackgroundThe CCN family has three Wnt-inducted secreted proteins named WISP-1, WISP-2 and WISP-3. These molecules are known to play a diverse role in cells,... |
SourceID | proquest pubmed crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 1909 |
SubjectTerms | Angiogenic Proteins - analysis Breast - pathology Breast cancer Breast Neoplasms - genetics Breast Neoplasms - pathology CCN Intercellular Signaling Proteins Cell Line, Tumor Cohort Studies Female Follow-Up Studies Gene Expression Regulation, Neoplastic Humans Insulin-Like Growth Factor Binding Proteins - analysis Intercellular Signaling Peptides and Proteins - analysis Intracellular Signaling Peptides and Proteins - analysis Lymphatic Metastasis - pathology Metastases Neoplasm Staging Patients Prognosis Proto-Oncogene Proteins - analysis Repressor Proteins RNA, Messenger - analysis Statistical analysis Transcription Factors - analysis Tumor suppressor genes Tumor Suppressor Proteins - analysis Tumors Wnt protein |
Title | Differential Expression and Prognostic Implications of the CCN Family Members WISP-1, WISP-2, and WISP-3 in Human Breast Cancer |
URI | https://www.ncbi.nlm.nih.gov/pubmed/17406949 https://www.proquest.com/docview/227366237 https://www.proquest.com/docview/2666090605 https://www.proquest.com/docview/70559483 |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEBZtAqWX0PTpJE116KlEVNbTOpVmsyEp7LK0Dd2bsfWAQrCT3Q3sLX-9I1m7baHNyQZJttDMaGY0o_kQeu_BFJJBaOJVCARUgCOV8hVxCtw4zVhj0w25yVRdXIkvcznPuTnLnFa52RPTRu16G8_IPzLQswp0tf50c0siaFQMrmYEjcdoN1UuA3bW862_VQLzyhTsVCDTTMkc1GRCxptzggsSz-lAPyuy_lst_cfWTDrn_Bnay8Yi_jxQdx898t1z9GSSw-Ev0P1ZhjcBMb3G43VOau1w0zk8W_QxiQ6G4ss_0sZxHzAYfXg0muIB9QJPfEQFWeIfl99mpDwZnuwkfSW9c_yzw-m4H5_GJPYVHkVmWbxEV-fj76MLkhEViBWMRtx5zrX3mnPpWyopdUa3NCjRcO5bLSL8dKzw1rjKCeGdbZQIXATbMmeELfkrtNP1nX-DsFWmoRV0MMELE5wBT5JZWZW2NRTaCkQ3C1rbXG48ol5c19HtABrUAw3qWDM50qBeF-jDdsjNUGvjoc6HGyrVWeyW9ZZJCnT0j1Zw1ShMjsoCvds2gzjFGEnT-f5uWcfiQkZUvECvB8r_nolOl4TNwYM_PkRPNxmFtDxCO6vFnX8LZsuqPU7MeYx2T8fT2ddfj4_obA |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrQRcEG9CC_UBLqgWXttxkgNCdLvVLu2uVtCK3kJiO1KlKml3t2I58Yv4j8zksYAEvfWUSLYTyzP2zHgeH8Arj6pQWOiIe1MUHEWA47HxMXcGzbhIyszWGXKTqRmd6I-n4ekG_OxyYSissjsT64PaVZbuyN9KlLMGZXX0_uKSE2gUOVc7BI2GKw79929osS3ejfeRvK-lPBgeD0a8BRXgVktB0OtKRd5HSoU-F6EQLolyURidKeXzSBMCMxU5y1zstPbOZkYXShc2ly7Rtq_wu7dgU1NCaw8294bT2ae12wK3S1i7Vw2eItKErRtV6pBy9bTSnG4GUSMwfPW3IPyPdltLuYP7cK9VT9mHhp8ewIYvH8LtSeuAfwQ_9ltAFTwYztlw1YbRliwrHZvNKwrbw6Fs_EegOqsKhmomGwymrMHZYBNPOCQL9mX8ecb7u81T7tZfqd8VOytZ7WBgexQ2v2QDYs_5Yzi5keV-Ar2yKv0zYNYkmYixQ1J4nRQuQdtV2jDu2zwR2BaA6BY0tW2Bc8LZOE_J0EEapA0NUqrSTDRIVwG8WQ-5aKp7XNd5q6NS2m70RbpmywC2_9GKxqHAyYkwgJ11M25g8spkpa-uFimVM0p0rAJ42lD-90yiOi05eX7tj3fgzuh4cpQejaeHW3C3i2cU_W3oLedX_gUqTcv8ZcuqDL7e9O74BZKwJGA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIlVcUHmnLdQHuKBadWzHTg4IwW5XXcquVoKKvYXEDwmpSsruViwnfhf_jnEeC0jQW0-JZDuxPDOeGc94PoDnDk2hxEtNnfKeogqwNFUupVahG6c5L0xzQ24yVafn8t08mW_Bz_4uTEir7PfEZqO2tQln5Mcc9axCXa2PfZcVMRuOXl9-pQFAKgRaezSNlkPO3Pdv6L0tX42HSOoXnI9OPg5OaQcwQI3kLMCwC6Gd00IkrmQJYzbTJfNKFkK4UsuAxhwKnhU2tVI6awolvZDelNxm0sQCv3sLbmuBRhWKkp5vfL0YBSdpAq0K9xOuki6gymUSbu1JIWk4I0TbQNH13yrxP3Zuo-9Gu3C3M1TJm5az7sGWq-7DzqQLxT-AH8MOWgW3iAtysu4SaitSVJbMFnVI4MOhZPxHyjqpPUGDkwwGU9IibpCJC4gkS_Jp_GFG46P2yY-arzTvgnypSBNqIG9DAv2KDAKjLh7C-Y0s9iPYrurKPQFiVFawFDtk3snM2wy9WG6SNDZlxrAtAtYvaG66UucBceMiDy4P0iBvaZCHes2BBvk6gpebIZdtnY_rOu_3VMo7kV_mGwaN4OAfregmMpwcSyI43DSjKIf4TFG5-mqZh8JGmUxFBI9byv-eiW4uKGd71_74EHZQJvL34-nZPtzpExtZfADbq8WVe4rW06p81vApgc83LRi_ACpCJyc |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Differential+Expression+and+Prognostic+Implications+of+the+CCN+Family+Members+WISP-1%2C+WISP-2%2C+and+WISP-3+in+Human+Breast+Cancer&rft.jtitle=Annals+of+surgical+oncology&rft.au=Davies%2C+Simon+R&rft.au=Watkins%2C+Gareth&rft.au=Mansel%2C+Robert+E&rft.au=Jiang%2C+Wen+G&rft.date=2007-06-01&rft.pub=Springer+Nature+B.V&rft.issn=1068-9265&rft.eissn=1534-4681&rft.volume=14&rft.issue=6&rft.spage=1909&rft_id=info:doi/10.1245%2Fs10434-007-9376-x&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=1282625731 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1068-9265&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1068-9265&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1068-9265&client=summon |